Albifimbrins A and B, a pair of epimeric tetrahydrofuran-containing linear polyketide derivatives from the marine-derived fungus Albifimbria verrucaria CD1-4

IF 1.3 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2024-05-20 DOI:10.1016/j.phytol.2024.05.006

Sheng-Tao Fang, Yin-Ping Song, Zhen-Zhen Shi, Nai-Yun Ji

引用次数: 0

Abstract

A pair of new epimeric polyketides, named albifimbrins A and B (1 and 2), were isolated from the cultures of the shellfish-derived fungus Albifimbria verrucaria CD1–4. Their structures were determined by extensive spectroscopic analysis including HR-MS, 1D and 2D NMR data, together with the CD exciton chirality method. Compounds 1 and 2 possess unusual tetrahydrofuran moiety in their linear molecule structures. The antimicroalgal assay indicated that compounds 1 and 2 shown moderate inhibitory activities against marine harmful microalgae, Prorocentrum donghaiense, Amphidinium carterae and Heterocapsa circulariaquama.

Abstract Image

查看原文本刊更多论文

Albifimbrins A 和 B，一对来自海洋真菌 Albifimbria verrucaria CD1-4 的含四氢呋喃的线性多酮衍生物

从源于贝类的真菌 Albifimbria verrucaria CD1-4 的培养物中分离出了一对新的表聚酮，命名为 albifimbrins A 和 B（1 和 2）。通过广泛的光谱分析，包括 HR-MS、一维和二维核磁共振数据，以及 CD 激发子手性方法，确定了它们的结构。化合物 1 和 2 的线性分子结构中含有不同寻常的四氢呋喃分子。抗微生藻试验表明，化合物 1 和 2 对海洋有害微生藻 Prorocentrum donghaiense、Amphidinium carterae 和 Heterocapsa circulariaquama 具有中等程度的抑制活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.